Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Ptcy Overcomes HLA Mismatch in Unrelated Donor Transplant for Acute Lymphoblastic Leukemia: A Study from the ALWP of the EBMT

Blood (2024) 144 (Supplement 1): 3570.

https://doi.org/10.1182/blood-2024-205455

Published: 2024

Journal Articles

Optimizing Haploidentical Transplant for Adults with Acute Lymphoblastic Leukemia: The Role of Donor and Graft Selection. a Study from the ALWP of the EBMT

Blood (2024) 144 (Supplement 1): 2193.

https://doi.org/10.1182/blood-2024-208242

Published: 2024

Journal Articles

No Differences in Transplant Outcomes with Post-Transplant Cyclophosphamide in One Antigen Mismatched Unrelated Donor Compared to Matched Unrelated Donor Recipients Receiving Antithymocyte Globulin in Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Blood (2024) 144 (Supplement 1): 693.

https://doi.org/10.1182/blood-2024-203472

Published: 2024

Journal Articles

Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Haploidentical Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Blood (2024) 144 (Supplement 1): 4944.

https://doi.org/10.1182/blood-2024-207391

Published: 2024

Journal Articles

SMART101 Donor T-Lymphoid Progenitors to Accelerate Immune Reconstitution Post HLA Mismatched Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide: Reset-02 First-in-Human Phase I/II

Raynier Devillier, Anne Huynh, Patrice Chevallier, Simona Piemontese, Regis Peffault de Latour, Patrizia Chiusolo, Aurelie Bauquet, Rahim Fandi, Sebastien Oster, Laura Simons, Isabelle Andre, Marina Cavazzana, Fabio Ciceri

Blood (2024) 144 (Supplement 1): 3457.

https://doi.org/10.1182/blood-2024-203203

Published: 2024

Journal Articles

Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT

Blood (2024) 143 (24): 2534–2543.

https://doi.org/10.1182/blood.2023023697

Published: 2024

Includes: Supplemental data

Journal Articles

Score to Guide Donor Choice in Haploidentical Stem Cell Transplant Using Post-Transplant Cyclophosphamide for Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Blood (2023) 142 (Supplement 1): 4932.

https://doi.org/10.1182/blood-2023-180075

Published: 2023

Journal Articles

Comparing Older Matched Related to Younger Matched Unrelated Donors in Acute Myeloid Leukemia in Remission Using Post-Transplant Cyclophosphamide

Simona Piemontese, Myriam Labopin, Goda Choi, Annoek E.C. Broers, Ellen Meijer, Gwendolyn Van Gorkom, Montserrat Rovira, Maria Jesús Pascual, Simona Sica, Jan Vydra, Aleksander Kulagin, Alexandros Spyridonidis, Arnon Nagler, Ali Bazarbachi, Bipin N. Savani, Eolia Brissot, Jaime Sanz, Mohamad Mohty, Fabio Ciceri

Blood (2023) 142 (Supplement 1): 1043.

https://doi.org/10.1182/blood-2023-182923

Published: 2023

Journal Articles

CNS Prophylaxis in Adult ALL Patients after Stem Cell Transplantation: An EBMT Survey on General Practice

Blood (2023) 142 (Supplement 1): 7049.

https://doi.org/10.1182/blood-2023-182831

Published: 2023

Journal Articles

Practice Patterns of Transplant Centers Regarding Maintenance Treatment Post Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: A Survey on Behalf of the EBMT Acute Leukemia Working Party

Blood (2023) 142 (Supplement 1): 7089.

https://doi.org/10.1182/blood-2023-187095

Published: 2023

Journal Articles

Patients Reported Outcomes (PROs) Are Still Unsatisfactory Among AML Long-Term Survivors: The Impact of Chronic GvHD in a Prospective Study on 15 Years Transplant Activity

Maria Teresa Lupo-Stanghellini, Camilla Riva, Alessandro Bruno, Simona Piemontese, Raffaella Greco, Sarah Marktel, Sara Mastaglio, Elisabetta Xue, Daniela Clerici, Francesca Farina, Fabio Giglio, Elisa Diral, Luca Vago, Consuelo Corti, Andrea A. Assanelli, Massimo Bernardi, Jacopo Peccatori, Matteo Giovanni Carrabba, Fabio Ciceri

Blood (2022) 140 (Supplement 1): 10571–10572.

https://doi.org/10.1182/blood-2022-169554

Published: 2022

Journal Articles

Endocrinopathies Following Allogeneic Stem Cell Transplantation: 10 Years Follow-up in 402 Patients

Blood (2018) 132 (Supplement 1): 4600.

https://doi.org/10.1182/blood-2018-99-117293

Published: 2018

Journal Articles

Post-Transplant Cyclophosphamide and Sirolimus in Matched Related and Unrelated Allogeneic Transplant with a Treosulfan-Based Conditioning

Jacopo Peccatori, Serena Albanese, MS, Raffaella Greco, MD, Francesca Lorentino, Fabio Giglio, MD, Daniela Clerici, MD, Lorenzo Lazzari, MD, Maria Teresa Lupo Stanghellini, Simona Piemontese, MD, Magda Marcatti, MD, Sara Mastaglio, MD, Andrea Assanelli, MD, Luca Vago, MD PhD, Consuelo Corti, MD, Massimo Bernardi, MD, Fabio Ciceri, MD

Blood (2018) 132 (Supplement 1): 4662.

https://doi.org/10.1182/blood-2018-99-111352

Published: 2018

Journal Articles

NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications

Antonio Russo, Giacomo Oliveira, Sofia Berglund, Raffaella Greco, Valentina Gambacorta, Nicoletta Cieri, Cristina Toffalori, Laura Zito, Francesca Lorentino, Simona Piemontese, Mara Morelli, Fabio Giglio, Andrea Assanelli, Maria Teresa Lupo Stanghellini, Chiara Bonini, Jacopo Peccatori, Fabio Ciceri, Leo Luznik, Luca Vago

Blood (2018) 131 (2): 247–262.

https://doi.org/10.1182/blood-2017-05-780668

Published: 2018

Includes: Supplemental data

Journal Articles

cGvHD — CIBMTR Risk Score Stratification in 207 Consecutive Adults after Unmanipulated PBSC Haploidentical Stem Cell Transplantation

Blood (2017) 130 (Supplement 1): 4499.

https://doi.org/10.1182/blood.V130.Suppl_1.4499.4499

Published: 2017

Journal Articles

Direct Costs in 4-Years Post Allogeneic Transplant Follow-up: A Comparative Analysis of 15 Matched Patients with and without GvHD

Blood (2017) 130 (Supplement 1): 5488.

https://doi.org/10.1182/blood.V130.Suppl_1.5488.5488

Published: 2017

Journal Articles

Voriconazole and Non-Melanoma Skin Cancer after Allogeneic HSCT: Results of a Prospective Dedicated Follow-up Program in 302 Patients

Blood (2016) 128 (22): 3442.

https://doi.org/10.1182/blood.V128.22.3442.3442

Published: 2016

Journal Articles

Disease Risk Index (DRI) Score Stratification and Composite End-Point GvHD-Free Relapse-Free Survival (GRFS) May Optimize Transplant Decision-Making Process in Haploidentical Stem Cell Transplantation

Blood (2016) 128 (22): 3492.

https://doi.org/10.1182/blood.V128.22.3492.3492

Published: 2016

Journal Articles

Allogeneic Genetically Modified T Cells (HSV-TK) As Adjunctive Treatment in Haploidentical Hematopoietic Stem-Cell Transplantation (haplo-HSCT) of Adult Patients with High-Risk Hematological Malignancies: A Pair-Matched Analysis from the Acute Leukemia Working Party of EBMT

Mohamad Mohty, MD PhD, Myriam Labopin, MD, Andrea Velardi, MD, Maria Teresa van Lint, MD, Donald Bunjes, Benedetto Bruno, MD PhD, Stella Santarone, MD, Johanna Tischer, Yener Koc, MD, Depei Wu, MDPhD, Zafer Gulbas, MD, Annalisa Ruggeri, MD, Florent Malard, MD PhD, Simona Piemontese, MD, Maria Teresa Lupo Stanghellini, MD, Chiara Bonini, MD, Claudio Bordignon, MD, Fabio Ciceri, MD, Arnon Nagler

Blood (2016) 128 (22): 672.

https://doi.org/10.1182/blood.V128.22.672.672

Published: 2016

Journal Articles

Post-Transplant Treatment with Ponatinib for Patients with High-Risk Philadelphia Chromosome Positive Leukemia

Blood (2016) 128 (22): 5810.

https://doi.org/10.1182/blood.V128.22.5810.5810

Published: 2016

NARROW

Ptcy Overcomes HLA Mismatch in Unrelated Donor Transplant for Acute Lymphoblastic Leukemia: A Study from the ALWP of the EBMT

Optimizing Haploidentical Transplant for Adults with Acute Lymphoblastic Leukemia: The Role of Donor and Graft Selection. a Study from the ALWP of the EBMT

No Differences in Transplant Outcomes with Post-Transplant Cyclophosphamide in One Antigen Mismatched Unrelated Donor Compared to Matched Unrelated Donor Recipients Receiving Antithymocyte Globulin in Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Haploidentical Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

SMART101 Donor T-Lymphoid Progenitors to Accelerate Immune Reconstitution Post HLA Mismatched Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide: Reset-02 First-in-Human Phase I/II

Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT

Score to Guide Donor Choice in Haploidentical Stem Cell Transplant Using Post-Transplant Cyclophosphamide for Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Comparing Older Matched Related to Younger Matched Unrelated Donors in Acute Myeloid Leukemia in Remission Using Post-Transplant Cyclophosphamide

CNS Prophylaxis in Adult ALL Patients after Stem Cell Transplantation: An EBMT Survey on General Practice

Practice Patterns of Transplant Centers Regarding Maintenance Treatment Post Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: A Survey on Behalf of the EBMT Acute Leukemia Working Party

Patients Reported Outcomes (PROs) Are Still Unsatisfactory Among AML Long-Term Survivors: The Impact of Chronic GvHD in a Prospective Study on 15 Years Transplant Activity

Endocrinopathies Following Allogeneic Stem Cell Transplantation: 10 Years Follow-up in 402 Patients

Post-Transplant Cyclophosphamide and Sirolimus in Matched Related and Unrelated Allogeneic Transplant with a Treosulfan-Based Conditioning

NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications

cGvHD — CIBMTR Risk Score Stratification in 207 Consecutive Adults after Unmanipulated PBSC Haploidentical Stem Cell Transplantation

Direct Costs in 4-Years Post Allogeneic Transplant Follow-up: A Comparative Analysis of 15 Matched Patients with and without GvHD

Voriconazole and Non-Melanoma Skin Cancer after Allogeneic HSCT: Results of a Prospective Dedicated Follow-up Program in 302 Patients

Disease Risk Index (DRI) Score Stratification and Composite End-Point GvHD-Free Relapse-Free Survival (GRFS) May Optimize Transplant Decision-Making Process in Haploidentical Stem Cell Transplantation

Allogeneic Genetically Modified T Cells (HSV-TK) As Adjunctive Treatment in Haploidentical Hematopoietic Stem-Cell Transplantation (haplo-HSCT) of Adult Patients with High-Risk Hematological Malignancies: A Pair-Matched Analysis from the Acute Leukemia Working Party of EBMT

Post-Transplant Treatment with Ponatinib for Patients with High-Risk Philadelphia Chromosome Positive Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only